

The *Helicobacter pylori* cytotoxin CagA is essential for suppressing host heat shock protein expression

Ben J. Lang^{1,5} · Rebecca J. Gorrell^{1,2} · Mona Tafreshi¹ · Masanori Hatakeyama³ · Terry Kwok^{1,2} · John T. Price^{1,4}

Received: 13 November 2015 / Revised: 11 January 2016 / Accepted: 10 February 2016 / Published online: 1 March 2016
© Cell Stress Society International 2016

Abstract Bacterial infections typically elicit a strong Heat Shock Response (HSR) in host cells. However, the gastric pathogen *Helicobacter pylori* has the unique ability to repress this response, the mechanism of which has yet to be elucidated. This study sought to characterize the underlying mechanisms by which *H. pylori* down-modulates host HSP expression upon infection. Examination of isogenic mutant strains of *H. pylori* defective in components of the type IV secretion system (T4SS), identified the secretion substrate, CagA, to be essential for down-modulation of the HSPs HSPH1 (HSP105), HSPA1A (HSP72), and HSPD1 (HSP60) upon infection of the AGS gastric adenocarcinoma cell line. Ectopic expression of CagA by transient transfection was

insufficient to repress HSP expression in AGS or HEK293T cells, suggesting that additional *H. pylori* factors are required for HSP repression. RT-qPCR analysis of HSP gene expression in AGS cells infected with wild-type *H. pylori* or isogenic *cagA*-deletion mutant found no significant change to account for reduced HSP levels. In summary, this study identified CagA to be an essential bacterial factor for *H. pylori*-mediated suppression of host HSP expression. The novel finding that HSPH1 is down-modulated by *H. pylori* further highlights the unique ability of *H. pylori* to repress the HSR within host cells. Elucidation of the mechanism by which *H. pylori* achieves HSP repression may prove to be beneficial in the identification of novel mechanisms to inhibit the HSR pathway and provide further insight into the interactions between *H. pylori* and the host gastric epithelium.

Electronic supplementary material The online version of this article (doi:10.1007/s12192-016-0680-x) contains supplementary material, which is available to authorized users.

Keywords *Helicobacter pylori* · CagA · Heat shock proteins · Heat shock response · Gastric cancer

✉ Terry Kwok
terry.kwok@monash.edu

✉ John T. Price
john.price@vu.edu.au

¹ Department of Biochemistry and Molecular Biology, Monash University, Clayton 3800, Victoria, Australia

² Infection and Immunity, and Cancer Programs, Monash Biomedicine Discovery Institute, Department of Microbiology, Monash University, Clayton 3800, Victoria, Australia

³ Division of Microbiology, Graduate School of Medicine, University of Tokyo, Tokyo 113-0033, Japan

⁴ Centre for Chronic Disease, College of Health and Biomedicine, Victoria University, St Albans, Melbourne, VIC, Australia

⁵ Present address: Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

Introduction

Heat shock proteins (HSPs) are a highly conserved protein family that functions as molecular chaperones to maintain the structural and functional integrity of cellular proteins. Upon disruption to protein homeostasis by proteotoxic insults such as heat stress, radiation, proteotoxic chemicals, reactive oxygen species, and infection, the production of HSPs is rapidly induced to recover proteostasis and promote cell survival. Induction of HSP expression is achieved by the activation of the transcription factor heat shock factor-1 (HSF1) and collectively, this response to proteotoxic stress is termed the heat shock response (HSR). HSPs function to maintain proteostasis by “holding” and “folding” proteins to promote their correct conformation, prevent mis-folded protein aggregates, and

target damaged proteins for degradation (Morimoto 2008). Importantly, the scope of HSP functions extend well beyond their chaperoning roles to the regulation of many cellular processes including but not limited to apoptosis, autophagy, senescence, inflammation, and immunity (Calderwood et al. 2012; Murphy 2013).

Most bacterial infections studied to date induce HSP expression with numerous studies showing activation of the HSR upon infection by bacterial pathogens such as *S. typhimurium*, *L. pneumophila*, *E. coli*, and *S. aureus* (Axsen et al. 2009; Shen et al. 2009; Zheng et al. 2004). In contrast to the upregulation of host-cell HSP expression associated with such bacterial infections, the gastric pathogen, *Helicobacter pylori*, has a novel ability to down-modulate host HSP expression upon acute infection of gastric epithelial cells (Axsen et al. 2009; Baek et al. 2004; Konturek et al. 2001; Pierzchalski et al. 2006; Targosz et al. 2006; Yeo et al. 2004). *H. pylori* is a Gram-negative, spiral bacterium that infects 50 % of humans globally. Infection with this bacterium is the strongest known individual risk factor for gastric cancer, which is the third leading cause of cancer-related death worldwide (Ferlay et al. 2012; Herrera and Parsonnet 2009). In addition to gastric cancer, *H. pylori* infection is also a major risk factor for the development of chronic gastritis, mucosa associated lymphoid tissue lymphoma (MALT) as well as gastric and duodenal ulcers (Bayerdorffer et al. 1997; Kuipers 1997). One of the major virulence factors of *H. pylori* strains is a 40-kb cytotoxin associated gene pathogenicity island abbreviated to *cagPAI*, which encodes a type IV secretion system (T4SS). This macromolecular complex belongs to a family of conserved secretion apparatuses that enable bacterial factors such as DNA and proteins to be translocated into host cells (Alvarez-Martinez and Christie 2009). For *H. pylori*, the cytotoxin CagA is the only T4SS protein substrate identified so far to be translocated into host cells upon infection (Asahi et al. 2000; Backert et al. 2000; Odenbreit et al. 2000; Stein et al. 2000). Upon translocation into the host cell, CagA undergoes tyrosine phosphorylation by host kinases at a number of Glu-Pro-Ile-Tyr-Ala (EPIYA) motifs in its carboxyl region (Asahi et al. 2000; Higashi et al. 2002; Odenbreit et al. 2000; Stein et al. 2000). Up to 20 host-binding partners of CagA have been identified, with CagA phosphorylation sites being highly promiscuous for host cell kinases (Backert et al. 2010). Studies have demonstrated complex activation of host signaling pathways by translocated CagA involving both CagA EPIYA phosphorylation-dependent and -independent mechanisms (Backert et al. 2010). To date, the bacterial factors responsible for the repression of HSP expression upon acute *H. pylori* infection in vitro remains unclear, with previous studies providing evidence both for and against a potential role for CagA in mediating this effect (Axsen et al. 2009; Targosz et al. 2006).

This study seeks to examine the underlying mechanisms by which *H. pylori* represses HSP expression. In doing so, this study aims to potentially identify novel mechanisms for inhibition of the HSR pathway, providing insight for both the therapeutic intervention of HSR and the pathogenic events of *H. pylori* infection.

Materials and methods

Mammalian cell culture

Human gastric adenocarcinoma cell line, AGS, or human embryonic kidney cell line, HEK-293T, were grown in RPMI or Dulbecco's modified Eagle's medium (DMEM), respectively. Both growth media were supplemented with 10 % FBS (Thermo Scientific) and for HEK293T, 1 % antimycotics/antibiotics (Gibco cat. 15240-062). Cells were incubated at 37 °C, 5 % CO₂. Brightfield images of cell lines and/or treated cells were obtained to examine cell morphology using an Eclipse TE-2000-U (Nikon) with 200× magnification.

H. pylori culture

H. pylori strain P12, previously designated strain 888-0, was isolated from a duodenal ulcer patient and contains both the *vacA* cytotoxin and a functional *cagPAI* (Fischer et al. 2010; Haas et al. 1993). *H. pylori* isogenic mutants P12Δ*cagL* (Gorrell et al. 2013), P12Δ*cagL/cagL* (Gorrell et al. 2013), P12Δ*cagPAI* (Odenbreit et al. 2001; Selbach 2002) and P12Δ*cagA* (kindly provided by S. Backert, Erlangen, Germany) were cultured and maintained as described previously (Gorrell et al. 2013). Broth cultures were shaken at 120 rpm overnight (approximately 16 h) prior to the day of infection and cell cultures were infected with *H. pylori* cultures that had attained an OD_{550nm} of 0.5-2.0.

Infection of AGS cells with isogenic mutant strains of *H. pylori*

The human gastric adenocarcinoma cell line AGS was cultured for infection experiments and inoculated with *H. pylori* liquid culture as described previously (Gorrell et al. 2013). AGS cells were plated in a 6-well dish (1×10^5 /well) or a 10-cm dish (7.5×10^5 /well) 48 h prior to infection in RPMI media supplemented with 10 % heat inactivated FBS. AGS cells were infected at a multiplicity of infection (MOI) of 50 with an equal volume of BHI broth added to the non-infected control.

Transient transfection

Both AGS and HEK293T cells were transfected at 70–90 % confluency with the expression vector pSP65/SR α -CagA-HA and pSP65/SR α -PR-CagA-HA to transiently express HA-tagged wild-type CagA (derived from *H. pylori* strain NCTC11637) and the HA-tagged phosphorylation-resistant CagA mutant, PR-CagA-HA (Higashi et al. 2002). Growth media was replaced with antibiotic free media, supplemented with 10 % FBS 2–3 h prior to transfection. Cells were transfected using Lipofectamine LTX and Plus reagent (Life Technologies) as per the manufacturer's protocol. Approximately 12–16 h later, cells were washed once with 1 \times PBS and full growth media was added.

Generation of stable cell lines

HEK293T cells were transiently transfected for virus production with the retroviral packaging vector pCL-Ampho (IMGENEX) and retroviral expression vectors using Lipofectamine LTX and plus reagent (Life Technologies) according to the manufacturer's instructions. Cell media was replaced 16 h following transfection, 24 h later the virus-containing media was collected and filtered using a 0.45- μ m filter. AGS cells were transduced with retroviral overexpression pBABEpuro-IRES-EGFP vectors expressing wild-type human HSF1 (HSF1WT) or a constitutively active mutant of HSF1 (HSF1 Δ RDT) (Fujimoto et al. 2005; Nguyen et al. 2013). GFP-positive transductants were selected by FACS as previously described (Lang et al. 2012).

Western blot analysis

For analysis of lysates of AGS or HEK293T cells, Western blot analysis was performed as outlined previously (Lang et al. 2012). For the protein sample preparation of *H. pylori*-inoculated cells, cell media was removed and equal volumes (approximately 100 μ l for 6-well dish) of 2 \times Laemmli buffer heated to 95 $^{\circ}$ C was added to each sample well. Cells were scraped and the sample collected and heated at 95 $^{\circ}$ C for 5 min, from which time it was stored at -20 $^{\circ}$ C. Protein samples prepared in RIPA lysis buffer (10–15 μ g of protein) or Laemmli buffer (15–25 μ l of sample) were loaded onto a 4–20 % Tris-glycine polyacrylamide gradient gel (NuSep), after which transfer and immunoblotting were performed as described previously (Lang et al. 2012). Antibodies used for immunoblotting: CagA (Santa Cruz, sc-25766), HSF1 (Enzo, ADI-SPA-901), HSF1 p-Ser³²⁶ (Epitomics, #2043-1), HSPA1A (Abcam, ab47455), HSPD1 (Thermo Scientific, MS120P1), HSPH1 (Santa Cruz, sc-6241), actin (BD Biosciences, 612656), anti-HA (Covance, MMS-101P). Chemiluminescent signals were captured by exposure to an X-ray film (GE healthcare or Fuji Film) and the resultant

signals quantified by densitometry using the ImageJ software (NIH). Densitometric data from multiple experiments were converted to mean fold change relative to actin expression before normalization to the control sample.

RT-qPCR analysis of gene expression

Total RNA was isolated using the Agilent Absolutely Total RNA extraction kit according to manufacturer's instructions. Total RNA was quantified by spectrophotometry and 1 μ g of RNA was reverse-transcribed using iScript Select cDNA Synthesis Kit (Bio-Rad) according to the manufacturer's instructions. cDNA (10 ng) was added to the qPCR reaction using SYBR Green PCR Master Mix (Life Technologies, catalog no. 4309155). Samples were loaded into the thermal cycler Rotorgene3000 with cycle conditions as follows; hold time: 10 min, 95 $^{\circ}$ C, Cycle: [95 $^{\circ}$ C, 15 sec; 60 $^{\circ}$ C, 60 sec] for 40 cycles. Data were analyzed using the LinRegPCR software, as outlined previously (Ruijter et al. 2009). Gene expression of human *HSPH1*, *HSPA1A*, *HSPD1*, *HSF1*, and *CXCL8* were normalized to that of the house keeping gene *RPL32*, and represented as fold change relative to the non-infected BHI control sample. Primer sequences for these genes are: *HSPH1* 5'-TGCAATACTTTCCCGGCAT-3' (forward) and 5'-ACAAAGCGGCCTATTTTGTCT-3' (reverse); *HSPA1A* 5'-GAGGCGTACCTGGGCTACCC-3' (forward) and 5'-GTTGAGCCCCGCGATCACAC-3' (reverse); *HSPD1* 5'-CCGACGACCTGTCTCGCC-3' (forward) and 5'-TGTTCTTCCCTTTGGCCCCAT-3' (reverse); *HSF1* 5'-CTGGCCATGAAGCATGAGAATG-3' (forward) and 5'-TGCACCAGTGAGATCAGGAAC-3' (reverse); *RPL32* 5'-CAGGGTTCGTAGAAGATTCAAGGG-3' (forward) and 5'-CTTGAGGAAACATTGTGAGCGATC-3' (reverse); and *CXCL8* 5'-CAGAGACAGCAGAGCACACA-3' (forward) and 5'-GGCAAACTGCACCTTCACA-3' (reverse).

Immunocytochemistry

Cells were cultured on 13 mm coverslips in a 24-well plate. Prior to fixation, cells were rinsed twice in PBS followed by the addition of 4 % paraformaldehyde for 15 min at 37 $^{\circ}$ C. Cells were permeabilized with 0.1 % Triton-X for 10 min at room temperature (RT) and washed thrice in PBS prior to immunostaining. Permeabilized cells were blocked with 10 % FBS/PBS for 30 min at RT. Primary antibodies, anti-HA (Covance, MMS-101P), and anti-HSF1 (Enzo ADI-SPA-901) were added at 1:1000 dilution and incubated overnight at 4 $^{\circ}$ C. Unbound antibody was removed by washing with PBS and an appropriate fluorophore-conjugated secondary antibody (Life technologies) was added at a dilution of 1:2500 and incubated for 1 h at RT. Unbound secondary antibody was removed by washing with PBS. DAPI (4',6-diamidino-2-

phenylindole, Life Technologies) was included as a nuclear stain.

Results

H. pylori-mediated repression of host HSPs expression is CagA-dependent

Given that CagA is one of the major virulence factors of *H. pylori* and the sole known protein delivered by the *cagPAI*-encoded T4SS into the host cell during infection, we investigated the importance of CagA for the altered HSP expression previously observed upon *H. pylori* infection in vitro (Axsen et al. 2009; Baek et al. 2004; Konturek et al. 2001; Pierzchalski et al. 2006; Targosz et al. 2006; Yeo et al. 2004). Wild-type *H. pylori* strain P12 (P12wt) and its CagA-deficient isogenic mutant (P12 Δ *cagA*) were used to infect the gastric adenocarcinoma cell line AGS to model *H. pylori* infection of gastric epithelia in vitro (Backert et al. 2001; Kwok et al. 2002; Kwok et al. 2007). Following 24 h of infection, HSP expression was quantitated by Western blot analysis. Co-culture of AGS cells with *H. pylori* P12wt induced a significant reduction in protein expression levels of HSPH1 (HSP105), HSPD1 (HSP60), and HSPA1A (HSP72). In contrast, the P12 Δ *cagA* mutant did not reduce expression of the aforementioned HSPs (Fig. 1a). *H. pylori* P12wt translocated CagA into the host cell under the experimental conditions used as shown by cell scattering and the acquisition of a ‘hummingbird’ cell morphology upon infection of AGS gastric epithelial cells with P12wt (Fig. 1b). The ‘hummingbird’ effect has previously been shown to be dependent upon an intact *cagPAI* and phosphorylation of translocated CagA (Backert

et al. 2001; Segal et al. 1999). Consistent with this, the P12 Δ *cagA* mutant did not induce ‘hummingbird’ morphology in infected AGS cells (Fig. 1b). All together, these results suggest that translocated CagA triggers down-modulation of host HSP expression.

Repression of host HSP expression requires an intact T4SS

To further examine a role for CagA translocation in HSR suppression, AGS cells were inoculated with *H. pylori* P12wt or deletion mutants lacking either the *cagL* gene (P12 Δ *cagL*) or the entire *cagPAI* (P12 Δ *cagPAI*). Deletion of *cagL* abolishes T4SS function, and deletion of *cagPAI* leads to deletion of the *cagA* gene and genes encoding the T4SS (Fischer et al. 2001; Kwok et al. 2007). In support of CagA translocation playing an essential role in *H. pylori* down-modulating host-cell HSP expression, inoculation with either the Δ *cagL* or Δ *cagPAI* mutants did not reduce HSPH1, HSPA1A, or HSPD1 protein expression (Fig. 2). When T4SS function was restored by re-introducing *cagL* into the Δ *cagL* strain, protein expression of HSPH1 and HSPD1 were significantly reduced to levels comparable with those observed in response to P12wt (Fig. 2). Together, these findings indicated that an intact T4SS, able to translocate CagA, is required for *H. pylori*-mediated repression of host HSP expression.

CagA is required but not sufficient for the down-modulation of host-cell HSP expression

To determine whether CagA was the sole factor responsible for *H. pylori*-mediated HSP repression, AGS cells




Fig. 1 *H. pylori*-mediated host HSP repression is CagA-dependent. **a** Western blot protein-expression analysis of chaperone proteins HSPH1 (HSP105), HSPA1A (HSP72), and HSPD1 (HSP60) in AGS cells 24 h post-inoculation (p.i.) with *H. pylori* P12wt, P12 Δ *cagA* mutant (MOI: 50), or culture broth control (BHI). Densitometric analysis of mean fold

change in expression normalized to BHI control from pooled experiments shown on right \pm SEM, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, $n = 5$ **b** Micrographs of AGS cell morphology upon co-culture with *H. pylori* P12wt or P12 Δ *cagA* mutant at 24 h p.i.




Fig. 2 *H. pylori*-mediated down-modulation of host HSPH1 and HSPD1 protein levels requires an intact T4SS. Western blot protein expression analysis of chaperone proteins following inoculation of AGS cells with *H. pylori* P12wt (as in Fig. 1) or isogenic mutant strains, P12ΔcagL ($n=5$), P12ΔcagL/cagL rescue ($n=4$) or P12ΔcagPAI ($n=6$) of *H. pylori* P12,

24 h p.i. The expression of CagA in the various *H. pylori* strains as detected by Western blot is also shown. Densitometric analysis of mean fold change in expression normalized to BHI control (ctrl) from pooled experiments shown on right (mean \pm SEM), * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$

were transiently transfected with expression vectors encoding HA-tagged CagA (CagA-HA) or a HA-tagged phosphorylation-resistant CagA mutant (PR-CagA-HA). The latter carries a tyrosine to alanine residue substitution in the EPIYA motifs, which contain the tyrosine phosphorylation sites in CagA (Higashi et al. 2002). We also examined the effect of ectopic CagA expression in HEK293T cells that show higher transfection efficiency than AGS cells, and greater gene expression from the SV40 promoter due to the presence of the T-antigen in this cell line. Ectopic expression of CagA-HA or PR-CagA-HA did not reduce HSP expression in either AGS (Fig. 3a) or HEK293T (Fig. 3b) cells. Taken together these results suggest that while HSP down-modulation by *H. pylori* infection requires CagA translocation, this effect may be dependent upon additional bacterial factors in conjunction with translocated CagA to achieve HSP repression in the host cell.

HSF1 is activated upon infection of AGS cells with *H. pylori*

To investigate the underlying mechanism by which *H. pylori* down-modulates the level of host-cell HSPs, the activity and expression of the transcriptional regulator of HSP expression, HSF1, was examined during AGS co-culture with either the *H. pylori* P12wt or P12ΔcagA mutant. Within 1 h of infection with either strain, phosphorylation of HSF1 at Ser³²⁶ was dramatically increased (Fig. 4). Ser³²⁶ is a positive regulation site critical for HSF1 transcriptional activity (Chou et al. 2012; Guettouche et al. 2005). Level of Ser³²⁶ phosphorylation was also increased at 3 h post-infection with either strain compared to that of the non-infected BHI control (Fig. 4). However at later time points, levels of HSF1 phosphorylated Ser³²⁶ in P12wt- or P12ΔcagA-infected cells were comparable to that of the BHI control. In contrast, there was no variation in HSF1 total protein level relative to the BHI control during the 24 h of




Fig. 3 Expression of *cagA* is not sufficient for down-modulation of HSPs in AGS or HEK293T cells. **a** AGS cells were transfected with 1.5 μ g of *cagA*-expression vector DNA or SR α vector control. Cell lysates were harvested 48 h post-inoculation and then analyzed by Western blot. Densitometry represents mean HSP/actin protein level ratios relative to that of the SR α vector control, \pm SEM, $n=2$. **b** HEK293T cells were

transiently transfected with 4.0 μ g of SR α expression vector containing CagA-HA or PR-CagA-HA, cell lysates were analyzed by Western blot 48 h following transfection. Densitometric analysis is shown on right with mean HSP levels normalized against actin control and expressed as fold change relative to non-transfected media control (ctrl) \pm SEM, $n=2$




Fig. 4 Phosphorylation of HSF1 at Ser³²⁶ upon infection with *H. pylori* P12wt and P12 $\Delta cagA$ mutant. Phosphorylation of HSF1 at Ser³²⁶ as well as HSF1 total levels within cell lysates of AGS infected with *H. pylori* P12wt or P12 $\Delta cagA$ for 1, 3, 6, 12, and 24 h were examined by Western

blot; representative blots are shown. Densitometric analysis of HSF1 p-Ser³²⁶/HSF1 mean expression ratio at 3-h p.i. ($n = 2$) and of HSF1/actin at 24-h p.i. ($n = 4$) is shown on right, \pm SEM

infection (Fig. 4). These data indicated that reduced HSP expression was not due to inhibition of HSF1 expression, or activation via phosphorylation.

Overexpression of HSF1 partially rescues the reduction in HSP levels upon *H. pylori* infection of AGS cells

To further examine whether CagA targets HSF1 during *H. pylori*-mediated down-modulation of HSPs, AGS cells stably overexpressing human HSF1 (HSF1WT) or a constitutive active mutant (HSF1 Δ RDT) were generated (Fig. S1b). Overexpression of HSF1WT or HSF1 Δ RDT resulted in increased levels of the HSF1 transcriptional targets HSPH1 and HSPD1 (Fig. 5a). HSP levels were examined by Western blot analysis of cell lysates harvested following 24 h of infection with *H. pylori* P12wt. Consistent with previous infections, HSP expression was significantly down-modulated in P12wt-infected GFP control cells (Fig. 5a). Concurrently, HSP levels were also markedly reduced in the HSF1WT- and HSF1 Δ RDT-overexpressing cell lines in response to infection with P12wt. However, the fold reduction in HSP expression was less than that of the AGS-GFP control-infected cells, indicating that while HSF1 overexpression partially rescued HSP expression, the primary mechanism for HSP repression by *H. pylori* is likely to be independent of HSF1 expression levels (Fig. 5a). In addition, the limited rescue effect observed upon overexpression of the constitutively active HSF1 Δ RDT suggests that *H. pylori*-mediated HSP repression is also independent of altered HSF1 activation.

The molecular basis of the inhibitory effect upon HSP expression during *H. pylori* infection was further investigated by co-localization analysis of CagA and HSF1. AGS cells were transiently transfected with expression vectors encoding CagA-HA or PR-CagA-HA. Endogenous HSF1 was predominantly nuclear in the AGS cell line, whereas ectopically expressed CagA was localized to the cell periphery (Fig. 5b).

The distribution of ectopically expressed CagA was in agreement with the previous observations that CagA upon translocation into or ectopic expression within the host cell was localized to the host-cell plasma membrane and cytoplasm (Backert et al. 2000; Higashi et al. 2002). The disparate cellular localisation of HSF1 and CagA indicated no direct interaction between the two molecules, and that the ectopic expression of CagA did not alter the nuclear localization of HSF1.

Activation of HSF1 upon infection of AGS cells with *H. pylori* does not result in elevated levels of HSP gene expression

Our findings suggest that despite the strong phosphorylation of HSF1 within 3 h of infection with *H. pylori* P12wt and P12wt $\Delta cagA$ mutant, HSP expression is reduced at 24 h post-infection. To determine whether *H. pylori*-mediated down-modulation of HSP levels was due to an inhibition of HSP gene transcription, RT-qPCR analysis of HSP mRNA levels was performed using samples collected at 4 h (data not shown) and 8 h post-infection with P12wt and P12 $\Delta cagA$ (Fig. 6). Consistent with the constant relative HSF1 protein levels observed up to 24 h post-infection (Fig. 4), no change in *HSF1* mRNA level was observed at 4 h (data not shown) or 8 h post-infection (Fig. 6). Despite significantly increased HSF1 phosphorylation up to 3 h post-infection (Fig. 4), and a robust infection indicated by upregulation of *CXCL8*, which encodes the proinflammatory chemokine interleukin-8 (Fig. 6), there was no concurrent increase in the mRNA levels of *HSPH1*, *HSPA1A*, or *HSPD1* (Fig. 6). This suggests that the activation of these genes by HSF1 may be somewhat limited during *H. pylori* infection. Moreover, no significant reduction in HSP gene expression was observed at these time points to directly account for the reduced HSP expression observed within the cells at 24 h post-infection. Furthermore, no CagA-dependent effect upon gene expression was found. Thus, these results indicate that the CagA-dependent mechanism of HSP down-modulation is unlikely to be due to inhibition of HSP gene transcription.




Fig. 5 Overexpression of HSF1 partially rescues HSP repression upon *H. pylori* infection of AGS cells. **a** AGS cells overexpressing HSF1 WT, HSF1 Δ RDT, and the GFP control cell line were inoculated with *H. pylori* P12wt (MOI:50) or BHI broth, and HSP levels were analyzed 24 h post-infection by Western blot, $n=3$. Densitometric analysis of mean fold change in HSPD1 levels \pm SEM are shown on right expressed as a ratio of that of the BHI control for each given cell line, $*p<0.05$. **b** CagA-expression vectors were used to transiently express CagA-HA or PR-CagA-HA in AGS cells. Immunostaining of AGS cells ectopically expressing CagA-HA and PR-CagA-HA using anti-HA and anti-HSF1 antibodies revealed no co-localization of CagA with endogenous HSF1. *Top two rows* represent secondary antibody control and empty SR α expression vector controls, respectively, $n=2$. Scale bar = 25 μ m

Analysis of HSP expression upon inhibition of proteasome activity with *H. pylori* infection

To examine whether reduced HSP levels observed at 24 h post-infection were mediated by enhanced proteasomal degradation of the HSPs, HSP levels in AGS inoculated with *H. pylori* P12wt and co-treated with the proteasome inhibitor MG132 were analyzed. In optimization of MG132 treatments, AGS cells were treated with a titration of MG132 concentrations for 24 h, with increasing levels of ubiquitinated protein seen up to MG132 concentration of 0.5 μ M (Fig. S1a).




Fig. 6 *H. pylori* infection does not alter HSP or HSF1 gene expression. RT-qPCR expression analysis of genes *HSPH1*, *HSPA1A*, *HSPD1*, *HSF1*, and *CXCL8* 8 h p.i. of AGS cells with either *H. pylori* P12wt or P12 Δ cagA mutant. Messenger RNA levels were normalized to that of the BHI control sample with *RPL32* used as a reference gene. *CXCL8* induction provided a positive control for robustness of infection, $n=3$

Treatment of cells with MG132 at concentrations of 1.0 μ M and higher caused increasing dose-dependent cellular toxicity (data not shown). While treatment with MG132 resulted in higher HSP expression in infected samples, this was matched by a comparable fold increase in HSP expression in the non-infected samples, likely due to the inherent HSR-activating properties of MG132 (Fig. 7). Accordingly, HSP levels were still substantially reduced in infected samples co-treated with MG132 compared to the non-infected BHI-inoculated cells. Although these data together do not exclude a contribution of proteasomal activity to HSP down-modulation, they strongly suggest that the primary mechanism of the *H. pylori*-mediated repression of HSP expression is not enhanced proteasomal degradation of HSPs.

Discussion

In addition to playing important roles in maintaining the integrity of cellular proteins and a cell's response to proteotoxic stress, HSPs also function in inflammation, immune signaling, and antigen presentation (Calderwood et al. 2012; Henderson et al. 2010). The gastric pathogen *H. pylori*, the primary cause of chronic gastritis, peptic ulcer, MALT, and gastric cancer, has been demonstrated to down-modulate host-cell HSP expression upon infection (Axsen et al. 2009; Baek et al. 2004; Konturek et al. 2001; Pierzchalski et al. 2006; Targosz et al. 2006; Yeo et al. 2004). The mechanism of *H. pylori*-mediated host HSP repression is currently unknown, the elucidation of which may provide novel insight into host-pathogen interactions and may prove valuable in the effort to develop anti-HSP strategies for cancer treatment.

The current study demonstrated reduced protein level of a number of HSPs, namely HSPH1, HSPA1A, and HSPD1, upon acute infection of the human AGS gastric




Fig. 7 MG132 treatment does not inhibit *H. pylori*-mediated HSP repression. AGS cells were treated with various concentrations of the proteasome inhibitor MG132 1 h prior to and during infection with *H. pylori* P12wt (MOI: 50) for a total of 24 h. Western blot analysis of protein expression following 24 h of combined infection and MG132

treatment is shown. Pooled densitometric values for HSPH1 ($n=2$) and HSPD1 ($n=3$) normalized to actin are shown on the right and represented as P12wt-infected expression relative to the non-infected BHI control sample for each respective MG132 concentration

adenocarcinoma cell line AGS with *H. pylori* strain P12. A number of previous studies have reported repression of host HSP expression upon *H. pylori* infection (Axsen et al. 2009; Baek et al. 2004; Konturek et al. 2001; Pierzchalski et al. 2006; Targosz et al. 2006; Yeo et al. 2004). This study is the first to report this effect using the *H. pylori* strain P12 in AGS cells. This further suggests that HSP repression by *H. pylori* is unlikely to be limited to certain strains or host-cell models. Of the HSPs examined in this study, the down-modulation of HSPA1A upon *H. pylori* infection has been the most frequently reported (Axsen et al. 2009; Pierzchalski et al. 2006; Targosz et al. 2006; Yeo et al. 2004). Axsen et al. reported a mild down-modulation of HSPD1 at 6 and 12 h in AGS but not KatoIII cells upon infection with the *H. pylori* strain J166. However, in contrast to this study, Axsen et al., found no significant reduction in protein expression of HSPD1 after 24 h of infection (Axsen et al. 2009). Yeo et al did not observe down-modulation of HSPD1 but repression of HSPB1 (HSP27) upon *H. pylori* infection; in contrast, Axsen et al. reported HSPB1 expression to be unaffected (Axsen et al. 2009; Yeo et al. 2004). The variable findings regarding which specific HSPs are repressed may be due to numerous experimental factors including strain-specific effects, the host-cell models used, the multiplicity of *H. pylori* infection used, as well as inconsistent infection periods between studies. However, although studies to date, including the current study, reveal variations in the individual HSPs repressed following *H. pylori* infection, reports are consistent in that unlike infection with other bacterial species, *H. pylori* infection results in some level of HSP repression rather than HSP upregulation.

This study identified for the first time that CagA acted as a bacterial factor essential for *H. pylori*-mediated repression of host HSP expression. In contrast, Axsen et al found reduced HSP expression upon *H. pylori* infection to be independent of CagA and the *cagPAI* (Axsen et al. 2009). Using semi-quantitative RT-PCR, Targosz et al., found that infection of human gastric MKN7 cells with *cagA*⁻ *vacA*⁻ *H. pylori* strain

326 also resulted in reduction of HSPA1A gene expression up to 72 h post-infection; however, this effect was more prominent during infection with *cagA*⁺ *vacA*⁺ *H. pylori*, suggesting that both CagA-dependent and independent mechanisms exist to mediate HSP repression (Targosz et al. 2006). This is in agreement with findings from the current study where no HSP-gene induction (i.e., levels higher than the non-infected BHI control) was observed upon *H. pylori* infection irrespective of whether the strain used for infection expressed CagA or not. Given that upon infection with either wild-type *H. pylori* or a CagA-deficient mutant there was a strong phosphorylation of HSF1 at Ser³²⁶, indicative of HSF1 activation, we were surprised that we did not see an associated elevation in HSP gene expression. This observation suggested the possibility that a CagA-independent inhibition of HSP gene expression is also in operation.

Ectopic expression of *cagA* isolated from the *H. pylori* strain NCTC11637 was found to be insufficient to significantly reduce HSP expression in either HEK293T or the AGS gastric cell line, indicating that CagA may require additional bacterial factors to mediate HSP reduction. Further confirmation of this phenomenon could be achieved by experiments that examine HSP expression upon ectopic transfection of *cagA* in other gastric cell models or primary human gastric cells. Nevertheless, the effect of CagA upon HSP expression shown here is reminiscent of the interactions of CagA with its host-binding partners, the specificity and affinity of which appear to vary depending on whether the CagA is translocated from *H. pylori* during infection or ectopically expressed. Thus these findings further emphasize the importance of additional bacterial factors for CagA-mediated effects during *H. pylori* infection, reviewed in (Backert et al. 2010).

The current study investigated the potential of CagA targeting the primary transcriptional regulator of HSPs, HSF1, as a mechanism for *H. pylori*-mediated HSP repression. Data presented here demonstrated that the repression of

HSP levels by *H. pylori* is mediated by a mechanism that is independent of any CagA-dependent alteration of HSF1 gene or protein expression. Gene expression levels of HSF1 were found to be unchanged 4 h (not shown) and 8 h post-infection, consistent with the report from Pierzchalski et al. where RT-PCR analysis of HSF1 gene expression was constant during *H. pylori* infection of KatoIII cells at time points examined up to 48 h (Pierzchalski et al. 2006). Moreover, the current study found that HSF1 protein levels remained constant relative to the non-infected control over 24 h, a time period at which HSP levels were significantly reduced in the infected host AGS cells. Together these findings indicate that the observed reduction in HSP expression is not due to a reduction in HSF1 expression. This is further supported by the finding that over-expression of wild-type human HSF1 or a constitutively active mutant of HSF1 Δ RDT was unable to significantly rescue *H. pylori*-mediated repression of HSP expression.

Interestingly, within 1 and 3 h of *H. pylori* P12wt infection of AGS cells, HSF1 phosphorylation at Ser³²⁶ was markedly increased. Phosphorylation of this serine residue has been shown to occur in response to proteotoxic stressors including heat stress, proteasome inhibition with MG132 and heavy metal exposure (CdCl₂) and single amino acid substitution of this residue dramatically reduces HSF1 transcriptional activity (Chou et al. 2012; Guettouche et al. 2005). This is the first study to identify phosphorylation of HSF1 at Ser³²⁶ during bacterial infection. Of note, infection with *H. pylori* P12wt or its isogenic Δ cagA mutant both induced phosphorylation of host-cell HSF1 to similar levels, indicating that CagA is not essential for this effect during *H. pylori* infection. Of note, the marked increase in HSF1 phosphorylation at Ser³²⁶ did not result in increased HSP gene expression at 4 h (not shown) or 8 h post-infection, suggesting a potential restriction of HSF1 transcriptional activity that prevented enhanced expression of HSPs. Both Aksen et al. and Targosz et al. demonstrated CagA-independent down-modulation of HSP and gene expression respectively (Aksen et al. 2009; Targosz et al. 2006), while the current study found that the ability of *H. pylori* P12 to down-modulate HSP levels was dependent on cagA, cagL, and an intact cagPAI. The finding that HSP and mRNA levels were not increased upon infection with either wild-type *H. pylori* or T4SS-defective mutants, despite apparent HSF1 activation, supports the possibility of CagA-independent restriction of HSP expression at the transcriptional level by *H. pylori*. Pierzchalski et al. proposed loss of HSF1 DNA-binding activity as a mechanism for the down-modulation of HSP levels during *H. pylori* infection upon formation of STAT1/HSF1 and STAT3/HSF1 complexes (Pierzchalski et al. 2006). Whether the formation of these complexes is indeed responsible for the observed down-modulation of HSP expression upon *H. pylori* infection remains to be investigated; if true this may present a potential mechanism for the apparent restriction of HSP gene

expression despite increased phosphorylation of HSF1 at the Ser³²⁶ site.

No CagA-dependent effect upon HSP gene expression was observed, suggesting translocated CagA may impact upon HSP expression at a post-transcriptional level. Yeo et al., provided evidence to suggest that down-modulation of HSPA1A protein level occurs within 2 h of *H. pylori* infection, which points to a more direct mode of HSP repression, independent of altered HSP gene expression (Yeo et al. 2004). Experiments within this study in which proteasome activity was inhibited with MG132 found no dramatic alteration in the fold repression of HSP expression upon *H. pylori* infection. However, while treatment with MG132 demonstrated proteasome inhibitory activity (Fig. S1a), complete proteasome inhibition was not confirmed. Further experiments would be needed to clarify any role for proteasomal degradation during HSP reduction by *H. pylori*.

Nevertheless, the data presented suggest a CagA-dependent block of HSP mRNA translation and/or altered HSP mRNA processing. Recently, acute *H. pylori* infection has also been shown to repress HSPA5 (Grp78/BiP) expression and the unfolded protein response (UPR). Despite significantly increased *HSPA5* gene expression upon infection and chemical activation of the UPR with tunicamycin, acute *H. pylori* infection was shown to repress both basal and tunicamycin-induced protein levels of HSPA5 (Baird et al. 2013). The increased production of host-cell proteins such as IL-8 upon infection (Brandt et al. 2005), suggests that any translational repression mediated by *H. pylori* is possibly specific to HSP transcripts. Specific repression of translation of HSP mRNAs has been described in other contexts; for example under basal conditions, translation of chicken reticulocyte HSP70 mRNA is restricted through a reduced elongation rate (Theodorakis et al. 1988). In addition, injection of IFN- γ and TNF- α , inflammatory factors that are also associated with *H. pylori* infection, were found to preferentially inhibit HSP translation without altering mRNA levels in a mouse model of colitis (Hu et al. 2007). Whether *H. pylori* infection plays a role in specific HSP repression via a mechanism similar to the previously mentioned contexts remains to be seen.

Conclusions

While the importance of CagA to the cytotoxicity of *H. pylori* infection and the development of disease are well established, it remains largely unclear how *H. pylori* benefits from translocating CagA into host cells (Backert et al. 2010). The current study has identified CagA to be a major factor for *H. pylori*-mediated HSP down-modulation upon infection. In addition to the HSPs previously known to be repressed by *H. pylori*, expression of HSPH1 has been identified for the first time in this study to be down-modulated by *H. pylori*, further

highlighting an apparent universal repression of stress-associated proteins by this pathogen. Given the immunoregulatory roles of HSPs, we hypothesize in agreement with Axsen et al., that *H. pylori* may benefit from CagA-dependent acute repression of HSP levels by modulation of the host immune response and thereby aiding the establishment of infection (Axsen et al. 2009). While CagA was shown to be essential for *H. pylori*-mediated repression of HSP expression, expression of CagA alone was not sufficient for this effect, highlighting the importance of additional bacterial factors. A specific mechanism for the repression of HSP expression has yet to be clearly identified; however, the data presented reveals an ‘uncoupling’ of HSP mRNA and protein expression similar to that previously reported (Baird et al. 2013). Future studies that identify the mechanism by which *H. pylori* mediates the repression of stress proteins may reveal a novel method to inhibit the HSR pathway; a strategy with significant potential for the treatment of numerous human cancers. Characterization and perturbation of *H. pylori*-mediated HSP repression will further our understanding of *H. pylori*-host interactions and may provide important insights into the pathogenesis of gastric diseases caused by *H. pylori* infection.

Acknowledgments National Health and Medical Research Council of Australia R Douglas Wright Fellowship No. 395525 (JP); Australian Postgraduate Award (BL); Monash Micro Imaging (MMI) for microscopy support. *H. pylori* strains P12, P12 Δ cagPAI, and P12 Δ cagA were kindly provided by Prof. Steffen Backert (Friedrich-Alexander University, Erlangen, Germany). HEK293T cells were kindly provided by Prof. Tony Tiganis (Dept. Biochemistry and Molecular Biology, Monash University).

References

- Alvarez-Martinez CE, Christie PJ (2009) Biological diversity of prokaryotic type IV secretion systems. *Microbiol Mol Biol Rev*: MMBR 73: 775–808. doi:10.1128/MMBR.00023-09
- Asahi M et al (2000) *Helicobacter pylori* CagA protein can be tyrosine phosphorylated in gastric epithelial cells. *J Exp Med* 191:593–602
- Axsen WS, Styer CM, Solnick JV (2009) Inhibition of heat shock protein expression by *Helicobacter pylori*. *Microb Pathog* 47:231–236. doi:10.1016/j.micpath.2009.08.002
- Backert S et al (2000) Translocation of the *Helicobacter pylori* CagA protein in gastric epithelial cells by a type IV secretion apparatus. *Cell Microbiol* 2:155–164
- Backert S, Moese S, Selbach M, Brinkmann V, Meyer TF (2001) Phosphorylation of tyrosine 972 of the *Helicobacter pylori* CagA protein is essential for induction of a scattering phenotype in gastric epithelial cells. *Mol Microbiol* 42:631–644
- Backert S, Tegtmeyer N, Selbach M (2010) The versatility of *Helicobacter pylori* CagA effector protein functions: the master key hypothesis. *Helicobacter* 15:163–176
- Baek H, Lim JW, Kim H, Kim JM, Kim JS, Jung HC, Kim KH (2004) Oxidative-stress-related proteome changes in *Helicobacter pylori*-infected human gastric mucosa. *Biochem J* 379:291–299
- Baird M et al (2013) The unfolded protein response is activated in *Helicobacter*-induced gastric carcinogenesis in a non-cell autonomous manner. *Lab Invest* 93:112–122. doi:10.1038/labinvest.2012.131
- Bayerdorffer E, Miehke S, Neubauer A, Stolte M (1997) Gastric MALT-Lymphoma and *Helicobacter pylori* Infection. *Aliment Pharmacol Ther* 11(Suppl 1):89–94
- Brandt S, Kwok T, Hartig R, König W, Backert S (2005) NF-kappaB activation and potentiation of proinflammatory responses by the *Helicobacter pylori* CagA protein. *Proc Natl Acad Sci U S A* 102: 9300–9305. doi:10.1073/pnas.0409873102
- Calderwood SK, Murshid A, Gong J (2012) Heat shock proteins: conditional mediators of inflammation in tumor immunity. *Front Immunol* 3:75. doi:10.3389/fimmu.2012.00075
- Chou SD, Prince T, Gong J, Calderwood SK (2012) mTOR is essential for the proteotoxic stress response, HSF1 activation and heat shock protein synthesis. *PLoS One* 7:e39679. doi:10.1371/journal.pone.0039679
- Ferlay J et al. (2012) GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC Cancer Base No. 11 [Internet]. International Agency for Research on Cancer; 2013., Lyon, France
- Fischer W, Puls J, Buhrdorf R, Gebert B, Odenbreit S, Haas R (2001) Systematic mutagenesis of the *Helicobacter pylori* cag pathogenicity island: essential genes for CagA translocation in host cells and induction of interleukin-8. *Mol Microbiol* 42:1337–1348
- Fischer W et al (2010) Strain-specific genes of *Helicobacter pylori*: genome evolution driven by a novel type IV secretion system and genomic island transfer. *Nucleic Acids Res* 38:6089–6101. doi:10.1093/nar/gkq378
- Fujimoto M, Takaki E, Hayashi T, Kitaura Y, Tanaka Y, Inouye S, Nakai A (2005) Active HSF1 significantly suppresses polyglutamine aggregate formation in cellular and mouse models. *J Biol Chem* 280: 34908–34916. doi:10.1074/jbc.M506288200
- Gorrell RJ et al (2013) A novel NOD1- and CagA-independent pathway of interleukin-8 induction mediated by the *Helicobacter pylori* type IV secretion system. *Cell Microbiol* 15:554–570. doi:10.1111/cmi.12055
- Guettouche T, Boellmann F, Lane WS, Voellmy R (2005) Analysis of phosphorylation of human heat shock factor 1 in cells experiencing a stress. *BMC Biochem* 6:4. doi:10.1186/1471-2091-6-4
- Haas R, Meyer TF, van Putten JPM (1993) Aflagellated mutants of *Helicobacter pylori* generated by genetic transformation of naturally competent strains using transposon shuttle mutagenesis. *Mol Microbiol* 8:753–760
- Henderson B, Calderwood SK, Coates AR, Cohen I, van Eden W, Lehner T, Pockley AG (2010) Caught with their PAMPs down? The extracellular signalling actions of molecular chaperones are not due to microbial contaminants. *Cell Stress Chaperones* 15:123–141. doi:10.1007/s12192-009-0137-6
- Herrera V, Parsonnet J (2009) *Helicobacter pylori* and gastric adenocarcinoma. *Clin Microbiol Infect* 15:971–976
- Higashi H, Tsutsumi R, Muto S, Sugiyama T, Azuma T, Asaka M, Hatkeyama M (2002) SHP-2 tyrosine phosphatase as an intracellular target of *Helicobacter pylori* CagA. *Protein Sci* 295:683–686
- Hu S et al (2007) Translational inhibition of colonic epithelial heat shock proteins by IFN-gamma and TNF-alpha in intestinal inflammation. *Gastroenterology* 133:1893–1904. doi:10.1053/j.gastro.2007.09.026
- Konturek JW et al (2001) Heat shock protein 70 (HSP70) in gastric adaptation to aspirin in *Helicobacter pylori* infection. *J Physiol Pharmacol* 52:153–164
- Kuipers EJ (1997) *Helicobacter pylori* and the risk and management of associated diseases: gastritis, ulcer disease atrophic gastritis and gastric cancer. *Aliment Pharmacol Ther* 11(Suppl 1):71–88
- Kwok T, Backert S, Schwarz H, Berger J, Meyer TF (2002) Specific entry of *Helicobacter pylori* into cultured gastric epithelial cells via a zipper-like mechanism. *Infect Immun* 70:2108–2120. doi:10.1128/iai.70.4.2108-2120.2002

- Kwok T et al (2007) *Helicobacter* exploits integrin for type IV secretion and kinase activation. *Nature* 449:862–866. doi:10.1038/nature06187
- Lang BJ et al (2012) Heat stress induces epithelial plasticity and cell migration independent of heat shock factor 1. *Cell Stress Chaperones* 17:765–778. doi:10.1007/s12192-012-0349-z
- Morimoto RI (2008) Proteotoxic stress and inducible chaperone networks in neurodegenerative disease and aging. *Genes Dev* 22:1427–1438. doi:10.1101/gad.1657108
- Murphy ME (2013) The HSP70 family and cancer. *Carcinogenesis* 34:1181–1188. doi:10.1093/carcin/bgt111
- Nguyen CH, Lang BJ, Chai RC, Vieusseux JL, Kouspou MM, Price JT (2013) Heat shock factor 1 impacts both positively and negatively upon cellular clonogenic growth depending upon p53 status. *Biochem J* 452. doi:10.1042/BJ20130098
- Odenbreit S, Puls J, Sedlmaier B, Gerland E, Fischer W, Haas R (2000) Translocation of *Helicobacter pylori* CagA into gastric epithelial cells by Type IV secretion. *Science* 287:1497–1500
- Odenbreit S, Gebert B, Puls J, Fischer W, Haas R (2001) Interaction of *Helicobacter pylori* with professional phagocytes: role of the cag pathogenicity island and translocation, phosphorylation and processing of CagA. *Cell Microbiol* 3:21–31
- Pierzchalski P, Krawiec A, Ptak-Belowska A, Baranska A, Konturek SJ, Pawlik WW (2006) The mechanism of heat-shock protein 70 gene expression abolition in gastric epithelium caused by *Helicobacter pylori* infection. *Helicobacter* 11:96–104
- Ruijter JM, Ramakers C, Hoogaars WM, Karlen Y, Bakker O, van den Hoff MJ, Moorman AF (2009) Amplification efficiency: linking baseline and bias in the analysis of quantitative PCR data. *Nucleic Acids Res* 37:e45. doi:10.1093/nar/gkp045
- Segal ED, Cha J, Lo J, Falkow S, Tompkins LS (1999) Altered states: involvement of phosphorylated CagA in the induction of host cellular growth changes by *Helicobacter pylori*. *Proc Natl Acad Sci U S A* 96:14559–14564
- Selbach M (2002) Functional analysis of the *Helicobacter pylori* cag pathogenicity island reveals both VirD4-CagA-dependent and VirD4-CagA-independent mechanisms. *Infect Immun* 70:665–671. doi:10.1128/iai.70.2.665-671.2002
- Shen X et al (2009) Targeting eEF1A by a *Legionella pneumophila* effector leads to inhibition of protein synthesis and induction of host stress response. *Cell Microbiol* 11:911–926. doi:10.1111/j.1462-5822.2009.01301.x
- Stein M, Rappuoli R, Covacci A (2000) Tyrosine phosphorylation of the *Helicobacter pylori* CagA antigen after cag-driven host cell translocation. *Proc Natl Acad Sci U S A* 97:1263–1268
- Targosz A, Pierzchalski P, Krawiec A, Szczyrk U, Brzozowski T, Konturek SJ, Pawlik WW (2006) *Helicobacter pylori* inhibits expression of heat shock protein 70 (HSP70) in human epithelial cell line importance of cagA protein. *J Physiol Pharmacol* 57:265–278
- Theodorakis NG, Banerji SS, Morimoto RI (1988) HSP70 mRNA translation in chicken reticulocytes is regulated at the level of elongation. *J Biol Chem* 263:14579–14585
- Yeo M et al (2004) Restoration of heat shock protein 70 suppresses gastric mucosal inducible nitric oxide synthase expression induced by *Helicobacter pylori*. *Proteomics* 4:3335–3342. doi:10.1002/pmic.200400951
- Zheng L, He M, Long M, Blomgran R, Stendahl O (2004) Pathogen-induced apoptotic neutrophils express heat shock proteins and elicit activation of human macrophages. *J Immunol* 173:6319–6326